1. Home
  2. HSAI vs MESO Comparison

HSAI vs MESO Comparison

Compare HSAI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSAI
  • MESO
  • Stock Information
  • Founded
  • HSAI 2014
  • MESO 2004
  • Country
  • HSAI China
  • MESO Australia
  • Employees
  • HSAI N/A
  • MESO N/A
  • Industry
  • HSAI
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HSAI
  • MESO Health Care
  • Exchange
  • HSAI Nasdaq
  • MESO Nasdaq
  • Market Cap
  • HSAI 1.8B
  • MESO 2.0B
  • IPO Year
  • HSAI 2023
  • MESO N/A
  • Fundamental
  • Price
  • HSAI $19.63
  • MESO $16.37
  • Analyst Decision
  • HSAI
  • MESO Buy
  • Analyst Count
  • HSAI 0
  • MESO 4
  • Target Price
  • HSAI N/A
  • MESO $18.00
  • AVG Volume (30 Days)
  • HSAI 3.9M
  • MESO 255.7K
  • Earning Date
  • HSAI 03-10-2025
  • MESO 03-04-2025
  • Dividend Yield
  • HSAI N/A
  • MESO N/A
  • EPS Growth
  • HSAI N/A
  • MESO N/A
  • EPS
  • HSAI N/A
  • MESO N/A
  • Revenue
  • HSAI $273,516,715.00
  • MESO $5,902,000.00
  • Revenue This Year
  • HSAI $14.55
  • MESO $140.44
  • Revenue Next Year
  • HSAI $61.44
  • MESO $318.31
  • P/E Ratio
  • HSAI N/A
  • MESO N/A
  • Revenue Growth
  • HSAI 11.22
  • MESO N/A
  • 52 Week Low
  • HSAI $3.52
  • MESO $1.91
  • 52 Week High
  • HSAI $20.18
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • HSAI 68.09
  • MESO 39.05
  • Support Level
  • HSAI $17.28
  • MESO $18.00
  • Resistance Level
  • HSAI $18.80
  • MESO $18.49
  • Average True Range (ATR)
  • HSAI 1.65
  • MESO 0.82
  • MACD
  • HSAI 0.13
  • MESO -0.41
  • Stochastic Oscillator
  • HSAI 91.38
  • MESO 1.75

About HSAI Hesai Group each ADS represents one Class B ordinary share

Hesai Group is engaged in the development, manufacture, and sales of three dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. The Group organized its operations into two segments: the LiDAR segment and the gas detection segment, out of which LiDAR segments derives maximum revenue. Geographically, the company operates into North America, Mainland China, Europe and Other regions.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: